Insider Trading June 24, 2026 09:41 AM

Stitch Fix CPO Bacos Offloads $282K in Shares Amid Tech Leadership Shift

Anthony Bacos executes sales under pre-established 10b5-1 plan as the company navigates post-earnings momentum and new AI initiatives.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
SFIX

Anthony Bacos, Stitch Fix's Chief Product and Technology Officer, sold 70,000 shares of Class A Common Stock in a series of transactions totaling $282,452. The sales, executed under a Rule 10b5-1 plan established in March 2026, followed the exercise of employee stock options. This executive transaction occurs against a backdrop of recent stock momentum, a leadership appointment, and the launch of new AI-driven features for the fashion retailer.

Stitch Fix CPO Bacos Offloads $282K in Shares Amid Tech Leadership Shift
SFIX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Executive Transaction: CPO Anthony Bacos sold 70,000 shares under a pre-established Rule 10b5-1 plan, following the exercise of employee stock options. This activity highlights the ongoing liquidity management and compensation structures within the retail technology sector.
  • Market Positioning: The sale comes as the stock has shown strong recent momentum, up nearly 13% over the past week. This price action intersects with broader market evaluations of the e-commerce and retail sectors, where investor sentiment is closely tied to valuation metrics and strategic AI integration.
  • Leadership and Innovation: Stitch Fix has appointed Sree Sreedhararaj as Chief Product and Technology Officer to lead technology, product, data science, security, and IT teams. Concurrently, the company has expanded its AI style visualization platform with a new feature called "See it on me," allowing clients to generate personalized images of themselves wearing recommended outfits.

Anthony Bacos, who serves as the Chief Product and Technology Officer at Stitch Fix, Inc. (NASDAQ: SFIX), recently executed the sale of 70,000 shares of the company's Class A Common Stock. The transactions, which took place on June 22, 2026, realized a total value of $282,452. The shares were divested at prices ranging between $4.0316 and $4.0436 per share. These sales were conducted pursuant to a Rule 10b5-1 plan that was established on March 17, 2026. Prior to the divestiture, Bacos acquired 50,000 shares through the exercise of employee stock options at a price of $2.48 per share, totaling $124,000. These options were part of an award where 25% vested on June 12, 2024, with the remainder vesting in quarterly installments over subsequent periods. Following these transactions, Bacos directly holds 1,071,994 shares of Stitch Fix Class A Common Stock and 622,543 employee stock options.

The executive transaction occurred as Stitch Fix shares have demonstrated notable recent momentum. The stock has climbed nearly 13% over the past week, trading at $4.42. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value estimate suggesting potential upside for investors. The sales were executed in two separate transactions. The first sale involved 50,000 shares at a weighted average price of $4.0316 per share, and the second sale consisted of 20,000 shares at a weighted average price of $4.0436 per share.

Key Points

  • Executive Transaction: CPO Anthony Bacos sold 70,000 shares under a pre-established Rule 10b5-1 plan, following the exercise of employee stock options. This activity highlights the ongoing liquidity management and compensation structures within the retail technology sector.
  • Market Positioning: The sale comes as the stock has shown strong recent momentum, up nearly 13% over the past week. This price action intersects with broader market evaluations of the e-commerce and retail sectors, where investor sentiment is closely tied to valuation metrics and strategic AI integration.
  • Leadership and Innovation: Stitch Fix has appointed Sree Sreedhararaj as Chief Product and Technology Officer to lead technology, product, data science, security, and IT teams. Concurrently, the company has expanded its AI style visualization platform with a new feature called "See it on me," allowing clients to generate personalized images of themselves wearing recommended outfits.

Risks and Uncertainties

  • Financial Performance vs. Analyst Outlook: Despite Stitch Fix reporting fiscal third-quarter 2026 results that exceeded Wall Street expectations, with an adjusted loss of $0.01 per share and revenue of $340.3 million surpassing the forecasted $332.56 million, the company faces continued skepticism. Mizuho reiterated an Underperform rating on the stock, maintaining a price target of $3.00 due to concerns over rising costs.
  • Valuation Discrepancies: While InvestingPro analysis suggests the stock appears undervalued at current levels with potential upside, the divergence between analyst price targets and recent market momentum highlights the uncertainty surrounding the company's valuation in the competitive retail and technology markets.

Following the strong third-quarter results, Stitch Fix raised its guidance for fiscal 2026 revenue and EBITDA. The company's ongoing efforts to enhance its offerings and leadership team are evident in the appointment of Sree Sreedhararaj and the expansion of its AI capabilities. These developments underscore the company's strategic focus on leveraging technology to drive customer engagement and operational efficiency in the digital retail space.

Risks

  • Financial Performance vs. Analyst Outlook: Despite Stitch Fix reporting fiscal third-quarter 2026 results that exceeded Wall Street expectations, with an adjusted loss of $0.01 per share and revenue of $340.3 million surpassing the forecasted $332.56 million, the company faces continued skepticism. Mizuho reiterated an Underperform rating on the stock, maintaining a price target of $3.00 due to concerns over rising costs.
  • Valuation Discrepancies: While InvestingPro analysis suggests the stock appears undervalued at current levels with potential upside, the divergence between analyst price targets and recent market momentum highlights the uncertainty surrounding the company's valuation in the competitive retail and technology markets.

More from Insider Trading

ACCESS Newswire Executive Brian Balbirnie Executes $11,725 Stock Divestment Jun 24, 2026 Horizon Kinetics Increases Stake in RENN Fund With $2,079 Share Purchase Jun 24, 2026 UroGen Pharma Insider Sale: CMO Schoenberg Offloads $350K in Shares Amid Patent Victory and Clinical Momentum Jun 24, 2026 EPR Properties Executive Sale and Q1 2026 Performance Review Jun 24, 2026 Oncology Institute Insider Jorey Chernett Adds to Position with $90k Share Purchase Jun 24, 2026